Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Changwei System Technology is a Shanghai-based biochip and integrated-circuit design company focused on specialty bio-integrated circuit chips for life science applications. The company has been described as the biochip subsidiary behind chips used in AnPac Bio's cancer screening and detection platform, with products already commercialized and in volume production. Its work appears centered on in vitro diagnostics and medical-device-enabling chips rather than therapeutic drug development. Public disclosures also indicate development activity for a new biochip related to a novel cancer treatment project and a biochip for an automatic drug injection device for diabetes patients. Overall, Changwei appears to be a small, active health-technology company operating at the intersection of semiconductors, diagnostics, and medical devices.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Changwei System Technology.